Phospho-BAD (S136) Antibody

What is BAD protein and why is phosphorylation at S136 significant?

BAD (Bcl-2-Associated Death promoter) is a pro-apoptotic protein with a molecular weight of approximately 23 kDa. The phosphorylation of BAD at serine 136 (S136) is a critical regulatory event that determines whether BAD promotes cell death or cell survival. When BAD is phosphorylated at S136, it is sequestered in the cytosol through binding to 14-3-3 proteins, preventing its interaction with anti-apoptotic proteins like Bcl-2 or Bcl-XL at the mitochondria . This phosphorylation effectively neutralizes BAD's pro-apoptotic function, promoting cell survival rather than apoptosis.

What are the key characteristics of commercially available Phospho-BAD (S136) Antibodies?

There are multiple Phospho-BAD (S136) antibodies available with distinct properties:

Polyclonal Antibody (#9295):

• Reactivity: Mouse

• Sensitivity: Detects only transfected levels

• MW (kDa): 23

• Source: Rabbit

• Application: Western Blotting (1:500 dilution)

Monoclonal Antibody (D25H8, #4366):

• Reactivity: Human, Mouse, Monkey

• Sensitivity: Detects endogenous levels

• MW (kDa): 23

• Source/Isotype: Rabbit IgG

• Applications: Western Blotting (1:1000 dilution), Immunoprecipitation (1:100 dilution)

These antibodies are specifically designed to detect BAD only when phosphorylated at the S136 residue, making them valuable tools for studying the activation state of this protein.

How do different phosphorylation sites on BAD interact with each other?

BAD contains multiple phosphorylation sites, including serine 112 (S112), serine 136 (S136), and serine 155 (S155), which collectively regulate its function. Research has shown that phosphorylation at S112 and S136 both contribute to BAD binding to 14-3-3 proteins, but with S136 playing the dominant role. Mutation of S136 to alanine causes complete loss of 14-3-3 binding, even when S112 and S155 are phosphorylated. In contrast, S112A BAD mutants can still bind 14-3-3 proteins at levels comparable to wild-type BAD .

Phosphorylation at S155 in the BH3 domain by PKA plays a different role - it directly blocks the dimerization of BAD with Bcl-xL, providing an additional mechanism for inhibiting BAD's pro-apoptotic function .

What are the optimal conditions for using Phospho-BAD (S136) Antibody in Western Blotting?

For optimal Western Blotting results with Phospho-BAD (S136) antibodies, researchers should follow these guidelines:

• Polyclonal antibody (#9295): Use at 1:500 dilution

• Monoclonal antibody (D25H8, #4366): Use at 1:1000 dilution

• Expected molecular weight: 23 kDa

• Sample preparation: Ensure proper phosphatase inhibitors are included during cell/tissue lysis to preserve phosphorylation status

• Controls: Include both positive controls (cells treated with growth factors known to activate Akt) and negative controls (phosphatase-treated samples)

Proper sample handling is critical as phosphorylation states can be rapidly lost if phosphatase inhibitors are not used effectively during sample preparation.

How can Phospho-BAD (S136) Antibody be used effectively in immunohistochemistry?

For immunohistochemical detection of phosphorylated BAD in tissue sections, researchers should follow this methodology:

• Incubate tissue sections with p-Bad (S136) antibody at a dilution of 1:50 overnight at 4°C

• Stain with 3,3'-diaminobenzidine (DAB) for visualization

• Counterstain with hematoxylin for nuclear visualization

• Dehydrate, treat with xylene, and mount for microscopic examination

For semiquantitative evaluation, an immunoscore system based on both percentage of stained cells and staining intensity can be employed. The intensity scoring system can be defined as: 0 (no staining), 1 (weak), 2 (moderate), 3 (strong), and 4 (very strong intensity) .

What approaches can be used for validating antibody specificity?

To validate the specificity of Phospho-BAD (S136) antibodies, researchers should implement multiple approaches:

• Phosphatase treatment control: Treating samples with lambda phosphatase should eliminate the antibody signal

• Blocking peptide competition: Pre-incubating the antibody with a phospho-S136 peptide should block specific binding

• Genetic validation: Using S136A mutant BAD-expressing cells as a negative control

• siRNA knockdown: Depleting endogenous BAD should eliminate the signal

• Stimulation experiments: Treating cells with known activators of the Akt pathway should increase the phospho-S136 signal

These validation steps are essential for ensuring experimental rigor and reproducibility when working with phospho-specific antibodies.

How does rapamycin affect BAD phosphorylation and what are the implications?

Treatment of human lung cancer cells with rapamycin results in enhanced phosphorylation of BAD at both S112 and S136, but not at S155. This phosphorylation is mediated through distinct pathways: the MEK/ERK pathway for S112 and the Akt pathway for S136 .

This increased phosphorylation represents a novel mechanism of rapamycin resistance, as phosphorylated BAD is sequestered and unable to promote apoptosis. Inhibition of MEK/ERK by PD98059 blocks S112 phosphorylation, while depletion of Akt by RNA interference blocks S136 phosphorylation. Simultaneous blockage of both phosphorylation sites significantly enhances rapamycin-induced growth inhibition in vitro and synergistically increases the anti-tumor efficacy of rapamycin in lung cancer xenografts .

These findings demonstrate the critical role of BAD phosphorylation status in determining therapeutic responses and highlight the potential for targeting these phosphorylation events to overcome drug resistance.

What is the molecular mechanism behind 14-3-3 protein binding to phosphorylated BAD?

The interaction between 14-3-3 proteins and phosphorylated BAD is a key regulatory mechanism that inhibits BAD's pro-apoptotic function. Research using in vitro binding assays has revealed that:

• Phosphorylation at S136 is the primary determinant for 14-3-3 binding

• Mutation of S136 to alanine completely abolishes 14-3-3 binding, even when S112 and S155 are phosphorylated

• The S112A BAD mutant retains binding to 14-3-3 at levels comparable to wild-type BAD

These findings indicate a hierarchical importance of phosphorylation sites in mediating 14-3-3 binding, with S136 playing the dominant role. When bound to 14-3-3 proteins, BAD is sequestered in the cytosol and prevented from interacting with and inhibiting anti-apoptotic proteins like Bcl-2 or Bcl-XL at the mitochondria .

How do kinase signaling pathways regulate BAD phosphorylation at S136?

BAD phosphorylation at S136 is regulated by multiple kinase signaling pathways:

• Akt/PKB pathway: The primary kinase responsible for phosphorylating BAD at S136 in response to growth factor signaling

• PI3K signaling: Activates Akt, leading to BAD phosphorylation

• mTOR feedback loop: Rapamycin treatment can paradoxically enhance Akt activity and increase BAD phosphorylation at S136

Experimental evidence shows that depletion of Akt by RNA interference blocks rapamycin-induced BAD phosphorylation at S136, confirming Akt's central role in this process . Understanding these regulatory pathways is crucial for developing therapeutic strategies targeting cell survival mechanisms in diseases like cancer.

How can manipulation of BAD phosphorylation overcome rapamycin resistance?

Targeting BAD phosphorylation represents a promising strategy for overcoming rapamycin resistance in cancer therapy. Research has demonstrated that:

• Inhibition of MEK/ERK by PD98059 blocks BAD phosphorylation at S112

• Depletion of Akt by RNA interference blocks BAD phosphorylation at S136

• Simultaneous blockage of both phosphorylation pathways significantly enhances rapamycin sensitivity

• Expression of non-phosphorylatable BAD mutant (S112A/S136A) can reverse rapamycin resistance

In xenograft models, the combination of Akt shRNA, PD98059, and rapamycin demonstrated enhanced anti-tumor efficacy compared to single or dual treatments . These findings suggest that therapeutic strategies targeting BAD phosphorylation pathways could potentially improve the efficacy of rapamycin and related mTOR inhibitors in clinical settings.

What experimental models are effective for studying BAD phosphorylation in vivo?

Several experimental models have proven valuable for studying BAD phosphorylation in vivo:

• Tumor xenograft models: H460 lung cancer cell xenografts in mice have been used to study the effects of manipulating BAD phosphorylation on tumor growth. Tumor volume is measured using the formula V=L×W²/2 (L: length; W: width)

• Genetically modified mouse models: Expression of phospho-mimetic or non-phosphorylatable BAD mutants can be used to study the physiological importance of specific phosphorylation sites

• Patient-derived xenografts (PDX): These models maintain the histological and molecular characteristics of the original tumor and can be used to assess BAD phosphorylation status in response to treatments

Immunohistochemical analysis using phospho-specific antibodies allows for assessment of BAD phosphorylation status in tissue sections from these models, with semi-quantitative scoring systems enabling comparative analyses .

How should researchers interpret changes in BAD phosphorylation in response to therapeutic interventions?

When interpreting changes in BAD phosphorylation in response to therapeutic interventions, researchers should consider:

• Baseline phosphorylation status: Establish the basal level of BAD phosphorylation before intervention

• Temporal dynamics: Monitor changes over time, as phosphorylation can be transient

• Pathway cross-talk: Consider that interventions may affect multiple pathways simultaneously

• Functional outcomes: Correlate phosphorylation changes with functional endpoints like apoptosis, cell survival, or tumor growth

• Compensatory mechanisms: Be aware that blocking one phosphorylation site may lead to compensatory phosphorylation at other sites